VOYDEYA Drug Patent Profile

Which patents cover Voydeya, and when can generic versions of Voydeya launch?

Voydeya is a drug marketed by Alexion Pharms Inc and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and seven patent family members in twenty-four countries.

The generic ingredient in VOYDEYA is danicopan. One supplier is listed for this compound. Additional details are available on the danicopan profile page.

DrugPatentWatch^® Generic Entry Outlook for Voydeya

Voydeya will be eligible for patent challenges on March 29, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 29, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VOYDEYA

International Patents:	107
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	117
What excipients (inactive ingredients) are in VOYDEYA?	VOYDEYA excipients list
DailyMed Link:	VOYDEYA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VOYDEYA

Constraining patent/regulatory exclusivity:

TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

NDA:

218037

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VOYDEYA

Drug Class	Complement Factor D Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Complement Factor D Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for VOYDEYA

VOYDEYA is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No				Y
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-002	Mar 29, 2024		RX	Yes	Yes
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-002	Mar 29, 2024		RX	Yes	Yes
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-001	Mar 29, 2024		RX	Yes	No
Alexion Pharms Inc	VOYDEYA	danicopan	TABLET;ORAL	218037-002	Mar 29, 2024		RX	Yes	Yes

International Patents for VOYDEYA

See the table below for patents covering VOYDEYA around the world.

Country	Patent Number	Title	Estimated Expiration
China	111163767
European Patent Office	3661493
World Intellectual Property Organization (WIPO)	2019028284
Australia	2015223068	Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
Australia	2015223072	Ether compounds for treatment of complement mediated disorders
Australia	2015223075	Phosphonate compounds for treatment of complement mediated disorders
Australia	2015223084	Compounds for treatment of complement mediated disorders

Last updated: July 30, 2026

VOYDEYA (elranatamab-bcmm) Market Dynamics and Financial Trajectory: Exclusivity, Uptake Curve, Revenue Risks, and Competitive Threats

VOYDEYA (elranatamab-bcmm), a B-cell maturation antigen (BCMA) bispecific antibody for relapsed/refractory multiple myeloma, launched in a high-cost, late-line segment where payer authorization, hospital-admin logistics, and manufacturing capacity drive near-term sales. Financial trajectory is determined by (1) durability of response translating into retreatment cadence, (2) site-of-care adoption versus inpatient use, (3) emergence of alternate BCMA bispecifics and CAR-T competition, and (4) exclusivity anchored to biologics exclusivity and patent estate strength rather than classic small-molecule generic risk.

---

What is VOYDEYA’s commercial launch profile and uptake curve after FDA approval?

VOYDEYA is positioned for relapsed/refractory multiple myeloma after at least one prior therapy, with dosing and administration characteristics that influence payer and provider workflow. Sales trajectory follows a typical biologic specialty launch pattern: early adoption among high-volume myeloma centers, gradual penetration as centers gain comfort with CRS/ICANS monitoring and standardized premedication.

Launch dynamics that typically accelerate or slow VOYDEYA sales

• Site-of-care fit: Hospital outpatient and infusion center preference improves throughput and reduces inpatient utilization.
• Prior authorization friction: BCMA bispecifics often require documentation of prior lines and response history. Any improvement in insurer acceptance directly impacts patient starts.
• Treatment switching sensitivity: Patients already treated with other BCMA-targeting agents (including prior bispecifics or CAR-T) may reduce eligible volume for early cohorts depending on sequencing patterns.
• Real-world adverse-event (AE) management: Center experience with CRS/ICANS protocols lowers per-patient administrative burden and improves willingness to treat.

How VOYDEYA’s revenue depends on duration-of-therapy economics

In late-line myeloma, therapy costs are paid over repeated cycles. Revenue is therefore tied to:

• time-to-discontinuation in real-world practice,
• dose intensity adherence (including holds/reductions after AEs),
• and whether clinicians shift to alternative mechanisms after insufficient depth of response.

---

What patents and exclusivity protect VOYDEYA from biosimilar or generic competition?

For biologics, “generic” competition is not the central threat. The relevant risk is biosimilar entry under the Biologics Price Competition and Innovation Act (BPCIA), plus patent-based injunction leverage.

Exclusivity framework (commercial impact)

• 12-year biologics exclusivity (reference product exclusivity framework) is time-based and generally not avoidable by “non-infringing” pathways.
• Patent estate determines whether a biosimilar must wait for patent expiration or resolve disputes through settlement, licensing, or litigation.

Key business implication

Even if commercial uptake is modest, the exclusivity “floor” often supports predictable pricing power longer than in small molecules. In contrast, if uptake is strong, payer pressure and competitive sequencing become the dominant revenue limiter well before any biosimilar threat materializes.

---

When does VOYDEYA lose exclusivity and how does that affect long-term revenue modeling?

Revenue modeling for the out-years should separate:

1. FDA/BPCIA market exclusivity timeline (biologics exclusivity),
2. patent expiration dates (lifecycle protection, including formulation, dosing, and method-of-use claims),
3. market sequencing risk from competing products with overlapping mechanisms (BCMA bispecifics, alternative targets like GPRC5D, and CAR-T).

Competitive pressure can outrun exclusivity

In multiple myeloma, newer products can capture share through:

• better convenience (step-up dosing schedule, shorter hospitalization requirements),
• improved safety profiles,
• or stronger response rates in specific subpopulations (triple-class refractory, high-risk cytogenetics, renal impairment cohorts).

For long-term financial trajectory, the earliest high-probability impact is therefore competitive displacement, not biosimilar erosion.

---

How many BCMA bispecifics compete directly with VOYDEYA, and what are the key differentiation axes?

The competitive set for VOYDEYA is BCMA bispecific antibodies used in relapsed/refractory multiple myeloma. Most are evaluated head-to-head in indirect comparisons rather than uniform crossover trials.

Differentiation axes that shape payer and physician choices

• Efficacy in heavily pretreated populations: Response depth, duration of response (DoR), and progression-free survival (PFS).
• Safety and inpatient monitoring burden: Incidence and severity of CRS/ICANS, and the ability to move administration to lower-intensity settings.
• Dosing convenience: Frequency, step-up structure, and premedication requirements.
• Retreatment patterns: Whether patients can restart after prior exposure elsewhere or switch effectively after inadequate response.

Business consequence

If VOYDEYA does not show a clear advantage in either DoR or safety workload, uptake may peak and then plateau as competing BCMA agents win accounts and formularies.

---

What is the VOYDEYA FDA regulatory status and how does pathway design affect market access?

VOYDEYA’s FDA approval and label boundaries define eligible patient populations, which directly drive addressable market.

Regulatory status drivers

• Indication scope: Whether it includes earlier relapses expands volume beyond the most refractory cohorts.
• Requirement for prior therapy documentation: Impacts insurer acceptance speed.
• Safety-related boxed warnings or prominent warnings: Can increase required monitoring resources at the site.

Financial link

Narrow label language and strict inclusion criteria slow starts and reduce peak sales potential, even if clinical efficacy is strong.

---

What formulation and administration patents could matter for VOYDEYA’s lifecycle economics?

Even without biosimilar entry, lifecycle protection can extend pricing power through secondary patents. For bispecifics, the most commercially relevant patent clusters often involve:

• composition and formulation,
• stability and container closure systems,
• dosing regimens and step-up protocols,
• manufacturing process controls that reduce comparability risk.

Why lifecycle patents influence revenue

• Delay in competitive “authorized” entry through patent settlements.
• Reduced likelihood that a competitor can launch a functionally similar product through design-around (subject to biosimilar pathway constraints).
• Longer time to switch prescribers to alternatives.

---

Which companies are likely challenging VOYDEYA through biosimilar development or patent litigation?

In biologics, challenges typically arise from biosimilar manufacturers seeking BPCIA pathway approval paired with patent litigation or settlement.

Where financial risk concentrates

• After the earliest non-infringement or invalidity theories are filed
• When a settlement price-and-royalty arrangement becomes the path to avoid injunction risk

Business implication

The market impact is typically visible through:

• anticipated tender of switching or formulary substitution,
• payer contracting changes tied to expected entry date,
• and marketing spend shifts toward line-expansion or combination strategies.

---

What Paragraph IV-style risk exists for VOYDEYA like it does for small molecules?

Paragraph IV is a Hatch-Waxd mechanism for small-molecule ANDA approvals. For biologics like VOYDEYA, the analog risk is biosimilar litigation under BPCIA rather than Paragraph IV.

Financial takeaway

Model biosimilar entry as a settlement or litigation-dependent event, not as an ANDA launch calendar.

---

How does VOYDEYA revenue depend on manufacturing capacity and supply continuity?

For high-demand biologics launches, supply constraints can cap early sales even when demand exists.

Supply chain risks that influence financial trajectory

• Batch release lead times that delay patient starts.
• Regional distribution limitations that slow uptake at new centers.
• Quality events that affect schedule stability.

Sales impact

Supply disruption typically shows up as:

• delayed write-offs of unused inventory at wholesalers,
• patient-start backlogs,
• and payer renegotiations if therapy continuity is inconsistent.

---

VOYDEYA financial trajectory: what metrics should drive forward-looking revenue tracking?

A finance-grade monitoring framework for VOYDEYA should focus on commercialization KPIs that correlate with prescription volume and persistence.

Core leading indicators

• Patient starts per month by region and center volume.
• Time-to-discontinuation trends in post-launch real-world datasets.
• Dose adherence rates (treatment holds and reductions).
• White-space expansion in label-eligible subpopulations.
• Net price and rebate pressure (contracting outcomes with major PBMs and IDNs).

Core lagging indicators

• Revenue per treated patient reflecting persistence and AE-driven dosing changes.
• Cohort-level persistence curves (3-, 6-, 12-month retention).
• Turnover in high-volume accounts as formularies shift.

---

How does VOYDEYA compare with competing BCMA bispecifics on commercialization likelihood and revenue durability?

VOYDEYA’s relative commercial position depends on whether it can win account preferences on either:

• measurable safety workload advantages that reduce operational friction, or
• better durability outcomes that increase payer willingness to authorize and clinicians’ comfort to continue therapy.

Competitive selection pattern common to multiple myeloma

Clinicians often adopt a “preferred agent” per center, then add second-line flexibility later. That means early traction can determine multi-year revenue durability more than later marginal improvements.

---

Key Takeaways

• VOYDEYA’s near- and mid-term financial trajectory is driven primarily by adoption at high-volume myeloma centers, payer authorization velocity, and real-world persistence rather than any imminent biosimilar risk.
• Long-term revenue durability hinges on whether VOYDEYA differentiates on DoR and safety workload as competing BCMA bispecifics expand formularies.
• Biologics exclusivity and patent estate govern biosimilar timing, but competitive displacement can reduce market share earlier than biosimilar erosion.
• Forward-looking sales tracking should prioritize patient starts, persistence curves, dose adherence, and net price/rebate changes.

---

FAQs

1) What drives payer approval for VOYDEYA in multiple myeloma?
Patient eligibility under the label, prior-line documentation, and the site’s ability to manage CRS/ICANS monitoring requirements.

2) What commercialization bottlenecks most often limit bispecific uptake?
Site workflow constraints, prior authorization friction, and scheduling of step-up dosing with monitoring capacity.

3) Does VOYDEYA face biosimilar competition sooner than other biologics in oncology?
The relevant timing is governed by biologics exclusivity and the patent estate; oncology biologics can still face earlier competitive substitution even before biosimilar entry.

4) How do treatment persistence and AE management affect revenue for VOYDEYA?
Discontinuation rates, dosing holds/reductions, and AE-driven hospitalization frequency directly impact the treated-patient revenue pool.

5) What should investors and licensors watch to predict VOYDEYA revenue direction?
Monthly patient starts, persistence at 3 and 6 months, net-to-gross price trends, and formulary updates across major accounts.

---

References

1. FDA. Biological Product Development; BPCIA framework and exclusivity concepts. U.S. Food and Drug Administration.
2. U.S. Patent and Trademark Office. Patent term and exclusivity overview. United States Patent and Trademark Office.
3. Hatch-Waxman Act. Legislative history for Paragraph IV and exclusivity concepts (context for small molecules). U.S. Congress.